Kiniksa Pharmaceuticals International (NASDAQ:KNSA) CAO Michael Megna Sells 11,000 Shares

Key Points

• Kiniksa Pharmaceuticals International's CAO Michael Megna sold 11,000 shares at $34.84 each, totaling approximately $383,240, reducing his ownership by 22.44%.
• The company's stock recently reached a mid-day trading price of $35.48, with a market capitalization of $2.63 billion and a P/E ratio of 887.22.
• Kiniksa Pharmaceuticals reported an EPS of $0.23 for the last quarter, surpassing analysts' expectations of $0.18, alongside a revenue of $156.80 million.

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA - Get Free Report) CAO Michael Megna sold 11,000 shares of the stock in a transaction that occurred on Wednesday, September 3rd. The stock was sold at an average price of $34.84, for a total value of $383,240.00. Following the sale, the chief accounting officer owned 38,011 shares in the company, valued at approximately $1,324,303.24. This trade represents a 22.44% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Kiniksa Pharmaceuticals International Stock Performance

KNSA traded up $1.20 during mid-day trading on Wednesday, reaching $35.48. The stock had a trading volume of 600,208 shares, compared to its average volume of 675,074. The stock has a market capitalization of $2.63 billion, a P/E ratio of 887.22 and a beta of 0.20. The firm's fifty day simple moving average is $30.51 and its two-hundred day simple moving average is $26.21. Kiniksa Pharmaceuticals International, plc has a 52 week low of $17.82 and a 52 week high of $35.53.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA - Get Free Report) last announced its quarterly earnings data on Tuesday, July 29th. The company reported $0.23 EPS for the quarter, beating analysts' consensus estimates of $0.18 by $0.05. The firm had revenue of $156.80 million for the quarter, compared to analyst estimates of $145.21 million. Kiniksa Pharmaceuticals International had a return on equity of 1.05% and a net margin of 0.90%. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. As a group, analysts expect that Kiniksa Pharmaceuticals International, plc will post -0.55 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research analysts have commented on KNSA shares. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a "strong-buy" rating to a "buy" rating in a research report on Saturday. Wedbush reiterated an "outperform" rating and issued a $36.00 price objective on shares of Kiniksa Pharmaceuticals International in a research report on Monday, July 21st. Wells Fargo & Company increased their price objective on Kiniksa Pharmaceuticals International from $30.00 to $42.00 and gave the company an "overweight" rating in a research report on Wednesday, July 9th. Finally, Jefferies Financial Group increased their price target on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a "buy" rating in a research note on Tuesday, July 29th. Six research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $41.17.

Institutional Trading of Kiniksa Pharmaceuticals International

Hedge funds have recently added to or reduced their stakes in the business. Wealth Enhancement Advisory Services LLC acquired a new stake in Kiniksa Pharmaceuticals International during the 1st quarter worth $301,000. GAMMA Investing LLC raised its stake in Kiniksa Pharmaceuticals International by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company's stock worth $27,000 after buying an additional 568 shares during the period. Deutsche Bank AG raised its stake in Kiniksa Pharmaceuticals International by 177.1% during the 1st quarter. Deutsche Bank AG now owns 394,522 shares of the company's stock worth $8,762,000 after buying an additional 252,125 shares during the period. Victory Capital Management Inc. acquired a new stake in Kiniksa Pharmaceuticals International during the 1st quarter worth $1,184,000. Finally, Nuveen Asset Management LLC raised its stake in Kiniksa Pharmaceuticals International by 7.3% during the 4th quarter. Nuveen Asset Management LLC now owns 795,612 shares of the company's stock worth $15,737,000 after buying an additional 54,361 shares during the period. Institutional investors and hedge funds own 53.95% of the company's stock.

About Kiniksa Pharmaceuticals International

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.